The effect of oral zingiber officinale supplement in hemodialysis patients with diabetes

Comparison of the effect of oral zingiber officinale supplement and placebo on pre-oxidant-antioxidant balance and glycemic control in diabetic hemodialysis patients: A double blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191109045382N2

Enrollment

Registered

2020-07-06

Start date

2020-02-09

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic hemodialysis. Type 2 diabetes mellitus with diabetic chronic kidney disease

Interventions

Intervention 1: Intervention group: Patients in this group will take 4 ginger capsules 500 mg daily (prepared by the researcher or capsule filling machine) for 8 weeks. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diabetic patients undergoing hemodialysis who have been on dialysis for at least 3 months Two or three dialysis sessions a week The duration of each session dialysis is 4 hours Patients who desire to enter the study Patients over 18 years of age

Exclusion criteria

Exclusion criteria: History of acute gastrointestinal disease History of Thyroid disorders History of gallstones Consumption of fish oil supplement Consumption steroid and non-steroidal anti-inflammatory drugs Consumption of Levothyroxine Consumption of Warfarin Consumption of antioxidant supplements History of ginger allergy Smoking

Design outcomes

Primary

Measure	Time frame
Prooxidant-antioxidant balance (PAB). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement by biochemical method and by ELISA kit.;Level of fasting blood sugar (FBS). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting blood sugar (FBS) by enzymatic method.;Level of insulin. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of insulin by enzymatic method.;HOMA-IR scores. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of HOMA-IR score using formula.	—

Measure

Time frame

Prooxidant-antioxidant balance (PAB). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement by biochemical method and by ELISA kit.;Level of fasting blood sugar (FBS). Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of fasting blood sugar (FBS) by enzymatic method.;Level of insulin. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of insulin by enzymatic method.;HOMA-IR scores. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of HOMA-IR score using formula.

—

Secondary

Measure	Time frame
Serum urea levels. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of serum urea level by enzymatic method.;Serum creatinine level. Timepoint: At the beginning of the study and 8 weeks after intervention. Method of measurement: Measurement of serum creatinine level by enzymatic method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHelya Rostamkhani

Tabriz University of Medical Sciences

helyarostamkhani@gmail.com+98 41 3340 8619

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026